Back to search

Article

pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcers: A Phase II, Double-Blind, Randomized Placebo-Controlled Trial

2020-11-05

Abstract excerpt

<h4>Background: </h4> Critical limb ischemia (CLI) has become a global problem. Less invasive therapy is needed. Hepatocyte growth factor (HGF) is one of the most potent angiogenic protein and the plasmid encoding human hepatocyte growth factor (HGF) is considered to be the most promising gene therapy for CLI.MethodsWe conducted a randomised, double-blind, placebo-controlled trial to assess the efficacy and safety...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
830e4516-ecac-5bea-8aa6-cb486a34fea7
DOI
10.21203/rs.3.rs-101447/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcers: A Phase II, Double-Blind, Randomized Placebo-Controlled TrialDOI 10.21203/rs.3.rs-101447/v1
Select a neighboring publication to make it the new centre.